Compare
Faeth Therapeutics, Inc. vs Gain Therapeutics, Inc. vs Immunic, Inc. vs Rein Therapeutics, Inc.
| Latest fiscal year | Faeth Therapeutics, Inc. FTH | Gain Therapeutics, Inc. GANX | Immunic, Inc. IMUX | Rein Therapeutics, Inc. RNTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$21.09M | -$20.16M | -$97.17M | -$49.87M |
| EPS (Diluted) | -$16.72 | -$0.61 | -$0.62 | -$1.96 |
| Operating cash flow | -$20.45M | -$18.47M | -$85.81M | -$19.36M |
| Free cash flow | -$20.47M | n/a | -$85.97M | n/a |
| Cash & equivalents | $8.67M | $20.84M | $15.48M | $3.21M |
| Total assets | $22.90M | $22.82M | $24.05M | $24.16M |
| Total liabilities | $4.31M | $4.25M | $30.73M | $7.24M |
| Shareholders' equity | $18.59M | $18.56M | -$6.67M | $16.92M |
| Return on year-end equity | -113.4% | -108.6% | n/a | -294.8% |
| Shares outstanding | 1.26M | 42.07M | 90.15M | 27.55M |
Revenue, most recent five fiscal years
| Fiscal year | Faeth Therapeutics, Inc. | Gain Therapeutics, Inc. | Immunic, Inc. | Rein Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $55.2K Ended 2023-12-31 | n/a | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $140.1K Ended 2022-12-31 | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $165.0K Ended 2021-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $28.9K Ended 2020-12-31 | n/a | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $0 Ended 2021-12-31 |